Fludarabine and cyclophosphamide

Phase 2Cell therapy

BBeijing Immunochina Medical Science & Technology Co., Ltd.

Fludarabine and cyclophosphamide is one of 28 small molecule programs targeting High Risk. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

High RiskRecruiting

Plasma Cell NeoplasmNot yet recruiting

ChidamideRecruiting

High RiskPhase 1

Recruiting

Plasma Cell NeoplasmPhase 1

Not yet recruiting

ChidamidePhase 2

Recruiting

Competition

Competitive Landscape

16 competitors in High Risk

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

1 2

Taxotere

AAvyxa

Phase 3

1 3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

1 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 5

Ursodeoxycholic Acid

Daewoong Pharmaceutical Co. LTD.

Phase 3

1 6

Opdivo

Bristol-Myers Squibb

Phase 2

3 7

Dacogen

Sun Pharmaceutical Industries, Inc.

Phase 2

3 8

Rydapt

Novartis

Phase 2

1 9

COLUMVI

Roche

Phase 2

1 10

Rituxan

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

High Risk

NCT07416682

Q3 2028

Phase 1Not yet recruiting

Plasma Cell Neoplasm

NCT06986434

Clinical

Trials by Indication[1]

Lymphoma1 trial

Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

Unknown status·PPeking University·Phase 1·NCT03208556·20 enrolled

Plasma Cell Neoplasm1 trial

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

Not yet recruiting·—·Phase 1·NCT06986434·20 enrolled

Safety and Efficacy1 trial

Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)

Completed·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1/2·NCT03173417·177 enrolled

Chidamide1 trial

Chidamide Bridging for CAR-T Therapy

Recruiting·—·Phase 1/2·NCT05370547·120 enrolled

B-cell Lymphoma1 trial

A Phase Ia Study of Tri-specific CAR19.20.22 Chimeric Antigen Receptor (CAR) T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

Enrolling by invitation·UUniversity of Maryland, Baltimore·Phase 1·NCT07168486·15 enrolled

1 more indication

High Risk1 trial

Clinical Study on the Safety and Efficacy of CAR BCMA-CD70 Dual-target CAR-T Therapy for High-risk Plasma Cell Neoplasms

Recruiting·AAffiliated Hospital to Academy of Military Medical Sciences·Phase 1·NCT07416682·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Fludarabine and cyclophosphamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fludarabine and cyclophosphamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fludarabine and cyclophosphamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Immunochina Medical Science & Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: BBeijing Immunochina Medical Science & Technology Co., Ltd.

Fludarabine and cyclophosphamide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2028

Trials by Indication[1]

Lymphoma1 trial

Plasma Cell Neoplasm1 trial

Safety and Efficacy1 trial

Chidamide1 trial

B-cell Lymphoma1 trial

High Risk1 trial

References

Drug Info

Quick Facts

Related News